QURE — uniQure N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590560 ·
Netherlands
Last close
$22.59
Market Cap
$1.57B
52W High
$71.50
52W Low
$8.73
ADV30
2,765,932
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,841,000 | 5,491,000 | -44,676,000 | -81,059,000 | 985,103,000 | 413,027,000 | 661,053,000 |
| Mar 2026 | 3,562,000 | 3,343,000 | -44,269,000 | -53,535,000 | 778,706,000 | 139,994,000 | 629,363,000 |
| Dec 2025 | 5,568,000 | 5,133,000 | -51,494,000 | -37,086,000 | 824,908,000 | 80,240,000 | 626,007,000 |
| Sep 2025 | 3,701,000 | 3,303,000 | -49,489,000 | -80,529,000 | 888,382,000 | 597,056,000 | 659,636,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-160,787,000
Investing CF
$-262,972,000
Financing CF
$584,350,000
CapEx
$-991,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.14
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,463,530,000
Inventory
$0
Receivables
$5,778,000
ST Investments
$397,308,000
EBIT TTM
$-185,479,000
Pretax Income TTM
$-245,170,000
Interest Exp TTM
$59,691,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,672,000
EBITDA
$-182,916,000
Free Cash Flow
$-77,580,000
Enterprise Value
$2,829,330,944
Total Cash
$810,334,976
Total Debt
$552,166,976
Shares Out
69,366,412
Trailing EPS
$-4.06
Book Value
$4.67
ROE
-157.6%
ROA
-15.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,098,000 | -187,827,000 | -198,971,000 | 824,908,000 | 626,007,000 | 198,901,000 | -177,963,000 |
| Dec 2024 | 27,119,000 | -182,180,000 | -239,556,000 | 556,536,000 | 563,288,000 | -6,752,000 | -182,728,000 |
| Dec 2023 | 15,843,000 | -282,486,000 | -308,478,000 | 831,689,000 | 624,019,000 | 207,670,000 | -145,929,000 |
| Dec 2022 | 106,483,000 | -144,246,000 | -126,789,000 | 704,964,000 | 228,955,000 | 476,009,000 | -145,060,000 |
TTM Snapshot
Revenues TTM
$18,093,000
NetIncome TTM
$-208,869,000
OpCashFlow TTM
—
Assets (Latest)
$778,706,000
Forward EPS
$-3.05
Max Pain — expiry 2026-10-16
max pain strike: $30.00 · spot: $22.59 · call oi: 28,845 · put oi: 14,009
Expected Move to 2026-10-16:
±$2.33
(10.29%) —
implied range
$20.27 –
$24.91
· ATM straddle on $23.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc. | $1.58B | $55.21 | — |
| KRSA | Korsana Biosciences, Inc. | $1.54B | $33.92 | — |
| STOK | Stoke Therapeutics, Inc. | $1.60B | $24.74 | — |
| INVA | Innoviva, Inc. | $1.53B | $21.21 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.53B | $15.48 | — |
News headlines (Yahoo Finance, 1h cache)
Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next
2026-10-07 13:09 · Yahoo
uniQure Plunges on Additional Data From Huntington's Disease Study
2026-09-30 16:47 · Yahoo
uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
2026-09-30 15:48 · Yahoo
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
2026-09-29 22:08 · Yahoo
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit
2026-09-29 20:02 · Yahoo
Why Is uniQure Stock Sinking on Tuesday?
2026-09-29 14:28 · Yahoo
UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 36%
2026-09-29 14:16 · Yahoo
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update
2026-09-29 13:31 · Yahoo
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update
2026-09-29 13:30 · Yahoo
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know
2026-09-29 12:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.